retatrutide cause cancer Since January 2026, there have been six cases of acute liver toxicity associated with unapproved peptide products labelled in Australia. These toxic effects may be linked to a contaminant in the Retatrutide, an experimental weight-loss drug,

Patients who combined resistance training with adequate protein intake preserved , and even gained , lean mass while losing over 25% of their body weight on semaglutide

Weight Wellness Take a science-backed approach to weight management with Garner's GLP-1 Pro, a targeted probiotic blend designed to naturally stimulate GLP-1your bodys satiety hormone

Last month, the U.S

Indications: Type 2 Diabetes Mellitus (monotherapy or add-on therapy) Especially useful in patients who cannot tolerate metformin or sulfonylureas Can be used in elderly and patients with mild renal impairment Approved Agents in India: Sitagliptin (Januvia) Vildagliptin (Galvus) Saxagliptin (Onglyza) Linagliptin (Trajenta) No renal dose adjustment needed Alogliptin (Nesina) Dosing: Once daily oral dosing Some agents require renal dose adjustment (except Linagliptin) Often combined with metformin or SGLT2 inhibitors Side Effects: Nasopharyngitis, headache GI upset (mild) Rare: Acute pancreatitis, severe joint pain, skin reactions Saxagliptin may slightly increase risk of heart failure in some patients Advantages Over Other Classes: Weight neutral Low risk of hypoglycemia Well tolerated in the elderly Convenient once-daily dosing Limitations: Modest HbA1c reduction (0.50.8%) Not effective in Type 1 Diabetes Less potent than GLP-1 analogs or SGLT2 inhibitors Conclusion: DPP-4 inhibitors are a safe, effective, and well-tolerated option for many patients with T2DM especially those needing an add-on to metformin or who can't tolerate injectables

Give yourself 10 minutes once a week, and let the rest of the week run on autopilot

Retatrutide: The first-in-class investigational triple receptor agonist redefining Type 2 diabetes therapy.